BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32527699)

  • 41. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 42. [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?].
    Pechère-Bertschi A; Ponte B; Wuerzner G
    Rev Med Suisse; 2020 May; 16(693):1003-1007. PubMed ID: 32401442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Facts and reflections on COVID-19 and anti-hypertensives drugs.
    Marin GH
    Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
    Son M; Seo J; Yang S
    Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The renin-angiotensin system - a therapeutic target in COVID-19?
    Sturrock BR; Milne KM; Chevassut TJ
    Clin Med (Lond); 2020 Jul; 20(4):e72-e75. PubMed ID: 32414711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
    Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
    Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
    [No Abstract]   [Full Text] [Related]  

  • 48. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity.
    Akoumianakis I; Filippatos T
    Obes Rev; 2020 Sep; 21(9):e13077. PubMed ID: 32567171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
    Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
    J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular disease and the impact of COVID-19.
    Yoganathan A; Sajjad MS; Harky A
    J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
    [No Abstract]   [Full Text] [Related]  

  • 51. What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.
    Wong SY; Brubaker AL; Wang AX; Taiwo AA; Melcher ML
    Clin Transplant; 2020 Jul; 34(7):e13991. PubMed ID: 32446267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
    Kai H; Kai M
    Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [ACE2 and coronavirus - a question of balance and dynamics?].
    Lundström A; Sandén P
    Lakartidningen; 2020 Apr; 117():. PubMed ID: 32314329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.
    Zheng H; Cao JJ
    Am J Pathol; 2020 Oct; 190(10):2013-2017. PubMed ID: 32735889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
    Casucci G; Acanfora D; Incalzi RA
    Drugs Aging; 2020 Nov; 37(11):779-785. PubMed ID: 33084001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Renin Angiotensin Axis, Angiotensin Converting Enzyme 2 and Coronavirus].
    Cano F; Gajardo M; Freundlich M
    Rev Chil Pediatr; 2020 Jun; 91(3):330-338. PubMed ID: 32730512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
    Vitiello A; Ferrara F
    Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
    Guo X; Zhu Y; Hong Y
    Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.